|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
2/14/2013 10:30:16 AM
TORONTO, Feb. 14, 2013 /CNW/ - Microbix Biosystems Inc. (TSX:MBX), a biotechnology company developing innovative biological products and technologies, today reported financial results for the first quarter of fiscal 2013 ending December 31, 2012. Revenue was $904,413 compared to $1,474,511 for the same quarter last year, a shortfall of $570,098. This decrease in quarterly revenue is attributable to two factors: (1) normal fluctuations in demand for viral antigens of $236,251 that are expected to generate sales growth in the remainder of 2013; and (2) decreased water sales of $323,542 that were the result of reduced production capacity. Operating expenses for the quarter were $1,111,272 compared to $1,159,534 for the same period last year, while the operating loss for the quarter was $701,660 compared to $517,746.
|
|
|
|
|
|
|
|
|
|
|